Objective:
The aim of the study was to offer comprehensive, country-specific insights into the 8 major markets, namely the US, EU5, Japan, and China, for HER2+ Metastatic Breast Cancer, focusing on the following points
- Key Statistics- HER2+ Breast Cancer
- Emerging Biomarkers in HER2+ BC patients
- Treatment Landscape- Regulatory approval details for branded agents, First-/Second-/Third-/Fourth-/Fifth- line systemic regimens in HER2+BC, Dosing and administration for common agents
- Epidemiology: Incidence and Prevalence/ Patient Pools, Relative Survival
- Treatment modalities- Systemic therapy, surgery, RT and others
- Clinical Trial Analysis (Ongoing Clinical Trials in HER2+ Metastatic BC)/ Pipeline Analysis
- Unmet Needs and Key Emerging Therapies
- Forecasting Insights- 1st , 2nd & 3rd line of therapy- Share by treatment modalities
Approach
For an in-depth exploration of HER2+ Metastatic Breast Cancer in the US, EU5, Japan, and China, our research begins with an extensive secondary analysis. This involves a comprehensive review of existing literature, market reports, and databases to glean insights into the current market landscape, treatment options, and prevailing trends. Additionally, a thorough examination of the regulatory and reimbursement landscapes in each country is undertaken to understand the specific dynamics influencing the market.
The primary research phase involves a particular approach to gathering first-hand insights from key stakeholders. Starting with the identification of key cancer centers and hospitals in the target markets. Regional Centers of Excellence (CoEs) are selected in the US based on their patient load and expertise in breast cancer treatment. Key Opinion Leaders (KOLs) within these CoEs are then identified and engaged to provide expert perspectives. Interviews with healthcare professionals within these centers yield valuable data on breast cancer prevalence, incidence, patient load, and the number of patients undergoing chemotherapy. Patient interviews add a crucial layer of understanding, capturing perspectives on symptom presentation, diagnosis experiences, current treatment paradigms, and unmet needs. This multidimensional primary research methodology ensures a comprehensive and detailed exploration of HER2+ Metastatic Breast Cancer across diverse regions, enriching the study with real-world insights.
Outcomes
The comprehensive study on HER2+ Metastatic Breast Cancer across the US, EU5, Japan, and China provided the crucial insights into the key statistics, emerging biomarkers, treatment landscapes, epidemiology, treatment modalities, clinical trial analyses, unmet needs, and forecasting trends. The analysis provided detailed information on disease incidence, prevalence, and patient pools, and on relative survival rates. The treatment landscape evaluation encompassed regulatory approvals, systemic regimens, and physician perceptions specifics for commonly used agents. Clinical trial analyses highlighted ongoing trials and upcoming therapies. Forecasting insights provided the details on the patient pools for different therapy lines, while unmet needs and emerging therapies addressed gaps in current treatment strategies. Overall, this study equips stakeholders with a comprehensive understanding of HER2+ Metastatic Breast Cancer, guiding informed decision-making in the diverse HER2+BC markets of the US, EU5, Japan, and China.
